GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2017, Gemphire Therapeutics Inc. (the Company) issued a
press release reporting its financial results for the first
quarter ended March 31, 2017.The press release is furnished as
Exhibit 99.1 and incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the
information included in this Current Report on Form 8-K
(including Exhibit 99.1) is furnished to Item 2.02 and shall not
be deemed to be filed for the purpose of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section.

About GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP)

Gemphire Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat cardiovascular and metabolic diseases. It is developing its product candidate, gemcabene (CI-1027), which is a once-daily, oral therapy for patients who are unable to achieve normal levels of low-density lipoprotein cholesterol (LDL-C) or triglycerides with approved therapies, primarily statin therapy. Gemcabene is liver-directed and inhibits apolipoprotein C-III (apoC-III) protein in the liver and may inhibit acetyl-CoA carboxylase (ACC) in the liver. Gemcabene blocks the overall production of hepatic triglycerides and cholesterol. Gemcabene has been tested as monotherapy and in combination with statins and other drugs in over 895 subjects, across approximately 18 Phase I and Phase II clinical trials. Gemcabene is used as an adjunctive therapy to reduce LDL-C, high-sensitivity C-reactive protein (hsCRP) and triglycerides.

GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) Recent Trading Information

GEMPHIRE THERAPEUTICS INC. (NASDAQ:GEMP) closed its last trading session down -0.08 at 11.16 with 21,377 shares trading hands.